Razvoj novih sistemskih zdravljenj pri bolnikih z razsejanim rakom prostate
Clinical development of new systemic therapies in patients with metastatic prostate cancer

Authors

  • Boštjan Šeruga Onkološki inštitut, Ljubljana
  • Tomaž Milanez Onkološki inštitut, Ljubljana
  • Simona Borštnar Onkološki inštitut, Ljubljana
  • Nataša Snoj Šarvari Onkološki inštitut, Ljubljana
  • Breda Škrbinc Onkološki inštitut, Ljubljana

Keywords:

systemic treatment, prostate cancer, Docetaxel

Abstract

Hormonsko zdravljenje s kastracijo je v začetku navadno učinkovito pri večini bolnikov z razsejanim rakom prostate, vendar bolezen čez čas neizbežno napreduje. Docetaksel v kombinaciji s prednizonom predstavlja standardno zdravljenje v prvi liniji zdravljenja bolnikov z razsejanim, proti kastraciji odpornim rakom prostate (rKORP). Do danes je bilo v kliničnih raziskavah preizkušenih več učinkovin v kombinaciji z docetakselom, vendar se nobena kombinacija ni izkazala za učinkovitejšo od docetaksela samega. Za bolnike z rKORP, pri katerih bolezen napreduje po zdravljenju z docetakselom, predstavljata kabazitaksel in abirateron acetat novi možnosti sistemskega zdravljenja.


Abstract (Eng)

Hormonal therapy with castration is initially effective in the majority of men with metastatic prostate cancer, but the disease invariably progresses. Docetaxel in combination with prednisone is the standard first-line treatment in men with metatstatic castration-resistant prostate cancer (mCRPC). Although several experimental agents have been evaluated in combination with docetaxel to date, none of these combinations improved the efficacy of docetaxel. Cabazitaxel and abirateron acetate are new options for systemic treatment in men with mCRPC who have progressive disease after treatment with docetaxel.

Downloads

Published

2011-12-15

How to Cite

Šeruga, B., Milanez, T., Borštnar, S., Snoj Šarvari, N., & Škrbinc, B. (2011). Clinical development of new systemic therapies in patients with metastatic prostate cancer. Onkologija : Slovenian Journal of Oncology, 15(2), 106–109. Retrieved from https://revijaonkologija.si/Onkologija/article/view/262

Issue

Vol. 15 No. 2 (2011)

Section

Review Article

License

The journal is published under the terms of the Creative Commons Attribution License CC-BY 4.0. The authors retain the copyright to their work without any restrictions whatsoever.

This journal is an open-access journal, meaning that all of its contents are freely accessible without any charge to the user or their institution. In accordance with the Budapest Open Access Initiative (BOAI) definition of open access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking for prior permission from the publisher or the author, provided the authors and the journal are appropriately credited.